Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.
Read more on PharmaceuticalOnline
Categories: Metastatic Breast Cancer Tags: combination, enrollment, initiate, Merrimack, MM121, Pharmaceuticals, Phase, SanofiAventis, Study
Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation
Hospira reaches legal settlement with Sanofi-Aventis over oxaliplatin injection patent litigation
Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira’s U.S. sales of its oxaliplatin injection, a generic version of Sanofi-Aventis’ oncolytic agent, Eloxatin®.
Read more on News-Medical-Net
Categories: Breast Cancer Research Tags: Hospira, injection, legal, litigation, Over, oxaliplatin, Patent, reaches, SanofiAventis, settlement